Development of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureus

dc.contributor.authorZhang, QingFeng
dc.contributor.authorJiang, TingTing
dc.contributor.authorMao, Xinrui
dc.contributor.authorKim, Jae Deog
dc.contributor.authorAhn, Dong Ho
dc.contributor.authorJung, Yunjin
dc.contributor.authorBae, Taeok
dc.contributor.authorLee, Bok Luel
dc.contributor.departmentMicrobiology and Immunology, School of Medicineen_US
dc.date.accessioned2023-05-30T18:39:59Z
dc.date.available2023-05-30T18:39:59Z
dc.date.issued2021
dc.description.abstractIn the Gram-positive pathogen Staphylococcus aureus, pore-forming toxins (PFTs), such as leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing host immune cells and red blood cells (RBCs). However, it remains unknown which combination of toxin antigens would induce the broadest protective immune response against those toxins. In this study, by targeting six major staphylococcal PFTs (i.e., gamma-hemolysin AB [HlgAB], gamma-hemolysin CB [HlgCB], leukocidin AB [LukAB], leukocidin ED [LukED], Panton-Valentine leukocidin [LukSF-PV], and alpha-hemolysin [Hla]), we generated 10 recombinant toxins or toxin subunits, 3 toxoids, and their rabbit antibodies. Using the cytolytic assay for RBCs and polymorphonuclear cells (PMNs), we determined the best combination of toxin antibodies conferring the broadest protection against those staphylococcal PFTs. Although anti-HlgA IgG (HlgA-IgG) showed low cross-reactivity to other toxin components, it was essential to protect rabbit and human RBCs and human PMNs. For the protection of rabbit RBCs, HlaH35L toxoid-IgG was also required, whereas for human PMNs, LukS-IgG and LukAE323AB-IgG were essential too. When the toxin/toxoid antigens HlgA, LukS-PV, HlaH35L, and LukAE323AB were used to immunize rabbits, they increased rabbit survival; however, they did not block staphylococcal abscess formation in kidneys. Based on these results, we proposed that the combination of HlgA, LukS, HlaH35L, and LukAE323AB is the optimal vaccine component to protect human RBCs and PMNs from staphylococcal PFTs. We also concluded that a successful S. aureus vaccine requires not only those toxin antigens but also other antigens that can induce immune responses blocking staphylococcal colonization.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationZhang Q, Jiang T, Mao X, et al. Development of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureus. Infect Immun. 2021;89(10):e0034221. doi:10.1128/IAI.00342-21en_US
dc.identifier.urihttps://hdl.handle.net/1805/33356
dc.language.isoen_USen_US
dc.publisherAmerican Society for Microbiologyen_US
dc.relation.isversionof10.1128/IAI.00342-21en_US
dc.relation.journalInfection and Immunityen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectStaphylococcus aureusen_US
dc.subjectImmunizationen_US
dc.subjectNeutralizing antibodiesen_US
dc.subjectToxinsen_US
dc.subjectVaccinesen_US
dc.titleDevelopment of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureusen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445174/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
iai.00342-21.pdf
Size:
1.78 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: